"Our partnership with G2L is an important step for us, as we develop a solution for the chronic care markets they serve," said Waqaas Al-Siddiq, biotricity founder and CEO. Affiliating with an organization like G2L gives biotricity multiple benefits such as identifying current gaps within existing solutions, a deeper understanding of all stakeholders, and the ability to pilot its solutions."As we move beyond the cardiac market¿, we will utilize G2L's diabetes and care management expertise to build a chronic care management platform for diabetes and other chronic illnesses," added Al-Siddiq. biotricity's mission is to develop multiple solutions for chronic illnesses by designing monitoring devices paired with chronic care management tools to improve patient compliance and empower the individual to take better care of their health. The Company's next generation medical-grade wearables will pave the way for the adoption of preventive care measures into mainstream healthcare practices. It will shift the current "reactive" model - where physicians diagnose and treat conditions and diseases after onset - to proactive. This is particularly true of managing heart-related illnesses, as patients often fail to comply with their doctor's medical directives, dietary changes, exercise regiments, and lifestyle alterations, without any feedback mechanism or continuous monitoring. biotricity has developed solutions that will initially work within the cardiac market as cardiovascular disease is the number one killer. About Global To Local Founded in 2010 through a partnership of Swedish Health Services, HealthPoint, Public Health Seattle & King County, and the Washington Global Health Alliance, along with the Cities of SeaTac and Tukwila, their demonstrate the effectiveness of global health strategies, techniques, methodologies, and technologies to improve the health status of underserved local communities with the goal of sharing learnings and scaling successes. Programs focus on drawing upon innovative, holistic and community-driven solutions to address health and economic development disparities in diverse, low-income populations. To learn more, visit www.globaltolocal.org. About biotricity , Inc. biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity's R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com. Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media ContactsMcCoin & Smith Communications Inc.Chris McCoin,Chris@mccoinsmith.com, 508-429-5988Richard Smith,email@example.com, 978-433-3304Investor Relations:Michael KoehlerLiolios Group, Inc.BTCY@liolios.com949-574-3860